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Abstract
Numerous studies have tested the association between TP53 mutations in ovarian cancer and prognosis but these
have been consistently confounded by limitations in study design, methodology, and/or heterogeneity in the
sample cohort. High-grade serous (HGS) carcinoma is the most clinically important histological subtype of ovarian
cancer. As these tumours may arise from the ovary, Fallopian tube or peritoneum, they are collectively referred
to as high-grade pelvic serous carcinoma (HGPSC). To identify the true prevalence of TP53 mutations in HGPSC,
we sequenced exons 2–11 and intron–exon boundaries in tumour DNA from 145 patients. HGPSC cases were
deﬁned as having histological grade 2 or 3 and FIGO stage III or IV. Surprisingly, pathogenic TP53 mutations were
identiﬁed in 96.7% (n = 119/123) of HGPSC cases. Molecular and pathological review of mutation-negative
cases showed evidence of p53 dysfunction associated with copy number gain of MDM2 or MDM4,o ri n d i c a t e d
the exclusion of samples as being low-grade serous tumours or carcinoma of uncertain primary site. Overall,
p53 dysfunction rate approached 100% of conﬁrmed HGPSCs. No association between TP53 mutation and
progression-free or overall survival was found. From this ﬁrst comprehensive mapping of TP53 mutation rate in a
homogeneous group of HGPSC patients, we conclude that mutant TP53 is a driver mutation in the pathogenesis of
HGPSC cancers. Because TP53 mutation is almost invariably present in HGPSC, it is not of substantial prognostic
or predictive signiﬁcance.
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Introduction
The gene TP53 that encodes the tumour suppressor
protein p53 is amongst the most commonly mutated
genes in human cancer [1]. The frequent presence of
TP53 mutations in ovarian cancer has been suggested
for almost two decades [2,3] and during this time,
approximately 70 publications have described the rela-
tionship between TP53 mutation status and clinical
outcome [4]. For such an intensively studied question,
there is a surprising degree of inconsistency in the
published data for both the prevalence of mutation and
association with prognosis or chemotherapy response.
A recent analysis of 64 publications reporting the
relationship of TP53 mutation to clinical outcome
found that only six studies fulﬁlled minimum qual-
ity criteria for the method of detecting mutations
or assignment of clinical response [5]. One of the
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most consistent limitations of previous p53 studies
is a reliance on p53 immunostaining as a surrogate
marker for TP53 mutation [4], even though this leads
to an unacceptable number of misclassiﬁcations [6].
Sequencing of tumour DNA is the gold standard to
detect different types of mutation and relate these to
clinical outcome. However, a recent review of 12 stud-
ies that sequenced TP53 in ovarian cancer found vari-
able mutation frequencies of 15–80% [5]. Inconsisten-
cies between these studies may relate to whether the
whole gene was or only the most commonly mutated
exons were sequenced. Additionally, most studies were
confounded by the inclusion of cases with different
histological types, stages, and grades of tumours [4].
Determining the true prevalence of TP53 muta-
tion is critical for understanding the pathogenesis of
high-grade serous cancers arising as ovarian, Fallop-
ian tube or primary peritoneal cancer. Although pre-
viously assumed to arise from the ovary, pathological
examination of the Fallopian tube from carriers with
BRCA1 or BRCA2 mutation has demonstrated that
tubal intraepithelial carcinomas (TICs) arising from
secretory epithelial cells in the ﬁmbria are the early
invasive lesion in high-grade serous (HGS) carcinoma
[7,8]. In addition, TICs are found in patients without
evidence of germline BRCA1 or BRCA2 lesions and
show concomitant TP53 mutations in the tube and in
pelvic metastases, further supporting the model that
TIC represents the origin of HGS carcinoma. HGS can-
cers may also arise from the peritoneum and although
these may have different epidemiological risk factor
proﬁles [9], they exist in a clinical continuum with
ovarian and Fallopian tube cancers. Hence we use
the term high-grade pelvic serous carcinoma (HGPSC)
[10] to recognize the frequent lack of clarity regarding
primary site in ovarian/Fallopian tube/peritoneal can-
cers and their overall biological and clinical similarity.
To address the limitations of previous studies and
determine accurately the relationship between TP53
mutation and HGPSC, we designed pilot and validation
studies to measure the mutation frequency in a homo-
geneous group of advanced stage HGPSC cancers from
a large population-based cohort.
Materials and methods
Samples and study design
The results of this study are presented in accordance
with reporting recommendations for tumour marker
prognostic studies (REMARK) criteria [11]. Supple-
mentary Figure 1 (Supporting information) summa-
rizes the ﬂow of patients through the pilot and valida-
tion study, including the number of patients included
in each stage of the analysis and reasons for exclusion.
Patients (n = 123) were selected from the Australian
Ovarian Cancer Study (AOCS), a population-based,
multicentre translational study that comprised prospec-
tive collection of bio-specimens and clinical and epi-
demiological data from patients with primary epithelial
ovarian, primary peritoneal, and Fallopian tube cancer
diagnosed between 2001 and 2005. Patients treated at
Westmead Hospital, Sydney between 1992 and 2002
(n = 22) were also included in the pilot cohort, mak-
ing an overall sample size of 145 HGPSCs. All women
in the pilot cohort received ﬁrst-line platinum-based
chemotherapy (cisplatin or carboplatin) with (n = 39)
or without (n = 6) the taxane paclitaxel. Similarly, the
majority of patients in the validation set received com-
bination platinum–taxane treatment (n = 93) or plat-
inum monotherapy (n = 4). Three patients (n = 3) did
not receive any chemotherapy, including one patient
with stage I cancer who declined treatment and two
patients who were too ill to receive chemotherapy. All
patients were prospectively consented using a proto-
col approved by the human research ethics committees
at multiple participating clinical and research centres.
Further details of the AOCS cohort can be found at
http://www.aocstudy.org. Statistical design and power
calculations are described in the Supporting informa-
tion, Supplementary methods.
TP53 sequencing
Coding TP53 exons 2–11 were ampliﬁed using
primers that encompassed the entire exon and exon–
intron boundaries. Puriﬁed PCR products were se-
quenced using an ABI 3100 genetic analyser (Applied
Biosystems, Warrington, UK). Sequencing reactions
were performed in forward and reverse directions.
Mutational analysis was performed using SeqScape
Software v2.6 (Applied Biosystems). Sequence traces
were aligned against the TP53 reference sequence
NC_000017. Independent, blinded sequencing of cases
from the pilot study was performed by the CR-
UK Mutation Detection Facility, Clinical Sciences
Building, Level 6, St James’s University Hospital,
Leeds, UK.
Characterization of mutation-negative HGPSC
cancers
For single nucleotide polymorphism (SNP) mapping
assay, SNP microarray data analysis, quantitative PCR
(qPCR), and immunohistochemistry, the reader is
referred to the Supporting information, Supplementary
methods.
aCGH data
Raw data ﬁles from aCGH experiments are available
from the Gene Expression Omnibus http://www.ncbi.
nlm.nih.gov/geo/ (Accession number GSE19416).
Results
Both treatment-responsive and primary resistant
HGPSCs have a high frequency of TP53 mutation
To estimate the number of samples required to detect
a signiﬁcant association between TP53 mutations and
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Figure 1. Characterization of TP53 mutation-negative cancer samples. (A) Summary plots of whole genome DNA copy number data for
seven mutation-negative samples. Red indicates chromosomal gain and blue shows regions of chromosomal loss. (B) High-resolution DNA
copy number analysis of MDM2,MDM4,a n dTP53 loci in each sample. The dotted line indicates the position of the gene within the region.
Samples with chromosomal gain or loss are marked with a red or blue asterisk, respectively. (C) Conﬁrmation of MDM2 and MDM4 copy
number gain using quantitative PCR of tumour DNA. Samples with gain are indicated in red. (D) Immunohistochemical staining of p53
protein in the following selected mutation-negative cases: case 41358; case 60258 (MDM2 gain); case 22029 (MDM4 gain); and case
60049 (MDM4 gain).
survival, we performed a pilot study with 45 HGPSCs
(ovarian, Fallopian tube, and primary peritoneal). The
cohort included 20 chemotherapy-resistant patients
who had tumour progression within 6 months of com-
pletion of treatment and 25 responsive patients who
did not progress for at least 9 months. The two groups
showed no statistically signiﬁcant differences in age,
tumour stage, residual disease or type of chemother-
apy (Table 1). Review of pathology reports showed one
patient with low-grade serous (LGS) carcinoma (case
450) and this case was excluded from further analysis.
Unexpectedly, pathogenic TP53 mutations were iden-
tiﬁed in 43 out of 44 patients included in the study
(Supporting information, Supplementary Table 1 and
Supplementary Figure 1). Mutations were compared
to Release 13 of the IARC TP53 mutation database
[12] and 20 cases had rare TP53 mutations, deﬁned as
less than ten occurrences (Supporting information, Sup-
plementary Table 1). From these, 12 were randomly
selected and independently conﬁrmed by a clinical
reference laboratory blinded to our results (data not
shown). Further analysis of mutations is described
below.
Conﬁrmation of high frequency of TP53 mutation in
an unselected population-based cohort of serous
cancers
To exclude the possibility that the high rate of TP53
mutations was biased by the selection criteria used
in the pilot study, we obtained additional serous
cancer cases that were a representative subset of
a large population-based series (Table 2). Mutations
were detected in 76/82 advanced-stage HGPSCs from
these cases, with no signiﬁcant difference between
the percentage of mutations in the matched validation
study compared with the pilot study (p = 0.3; Fisher
exact test).
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Table 1. A comparison between the clinical characteristics of the chemotherapy-resistant and -responsive patients in the pilot study
Resistant (n = 20) Responsive (n = 25) p (test)
PFS (months)
Median 10.2 23.3 <0.001 (log rank)
OS (months)
Median 21.4 57.3 <0.001 (log rank)
Age (years)
Median 58.26 58.7 0.7 (Wilcoxon rank sum)
Range 22.9–78 38.1–77.7
Stage (n)
III 20 23 0.5 (Fisher)
IV — 2
Chemotherapy (n)
Adjuvant 19 25 0.4 (Fisher)
Neo-adjuvant 1 0
Residual disease (n)
No residual disease 2 5 0.2 (Fisher)
≤1c m 1 1 8
>1c ma n d≤2c m 5 5
>2c m 1 6
Unknown 1 1
TP53 (n)
Wild type 1 0 0.4 (Fisher)
Mutant 19 25
OS = overall survival; PFS = progression-free survival, deﬁned as the period from diagnosis to the date of documented progression. Six samples (2 resistant, 4
responsive) did not have precise values for size <2c m .
Table 2. Clinical characteristics of the validation study patients
Validation set (n = 82
PFS (months)
Median 13.3
OS (months)
Median 34
Age (years)
Median 61.3
Range 40.4–79.3
Stage (n)
III 73
IV 9
Grade (n)
21 8
36 3
Unknown 1
Chemotherapy (n)
Adjuvant 71
Neo-adjuvant 11
Residual disease (n)
No residual disease 16
≤1c m 2 6
>1c ma n d≤2c m 5
>2c m 2 5
Unknown 10
TP53 (n)
Wild type 6
Mutant 76
OS = overall survival; PFS = progression-free survival.
TP53 mutations arise at high frequency in exons
2–4and9–11inHGPSCcarcinoma
We analysed the 119 mutations found in 126 HGPSC
cases from the pilot and validation set (Supporting
information, Supplementary Table 1). As expected, the
majority of TP53 mutations were missense muta-
tions (56.3%, n = 67/119) occurring in exons 4–8
(Supporting information, Supplementary Table 1). The
most frequently mutated codon was 273 (n = 9/67
cases, 13.4%) comprising R273C, R273H, and R273L
mutants. Analysis of exon and splice sites for exons
2–4 and 9–11, outside the DNA binding domain,
showed 12 (10.1%) and 10 (8.4%) mutations, respec-
tively, which taken together comprised 18.5% (n =
22/119) of all mutations in our series. Of note, a
total of eight mutations affected exon 10 (6.7%) in
the tetramerization domain (codons 324–356) and all
were predicted to cause truncation of the protein. Four
of these mutations occurred at g.16915 (codon 342).
In 717 serous sub-type ovarian, Fallopian, and pri-
mary peritoneal cancer cases in Release 13 of the
IARC TP53 database, 30 (4.2%) had mutations in
exons 2–4, 18 had mutations affecting exon 10 alone
(2.5%), and 20 (2.8%) had mutations in exons 9–11.
Twenty-two mutations from our series (n = 22/119,
18.5%) were not present in the IARC database. With
the exception of one, all were insertions or deletions
(Supporting information, Supplementary Table 1). The
remaining novel mutation in case 434 was at posi-
tion g.11602_11603GC>AA, creating a unique tandem
nonsense mutation.
Low-stage HGPSC cases have a high frequency of
TP53 mutations
The very high prevalence of mutation in high-stage
cases suggested that TP53 was an early event in
the pathogenesis of HGPSC. From the validation
set, 15 cases were stage 1 or 2 HGPSC and 13/15
(86.7%) had TP53 mutation (Supporting information,
Supplementary Table 1). The negative cases 41307
and 60111 had mixed endometrioid/HGS or grade
1 pathology, respectively. As for high-stage cases,
the majority of mutations (n = 10/13; 76.9%) were
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missense mutations in exons 5–8. There was one
nonsense mutation in exon 10 (7.7%) and two splice
junction mutations (15.4%).
Mutation-negative cases have alternative
mechanisms of p53 dysfunction
We considered the possibility that TP53 mutations
in the seven mutation-negative samples (pilot n =
1, validation n = 6) were missed because of con-
tamination with normal DNA. Although all samples
with signiﬁcant stroma were needle-dissected prior
to sequencing, pathological review of the mutation-
negative cases indicated that they did not have
increased stroma compared with mutation-positive
cases (data not shown). Additionally, array-based com-
parative genomic hybridization (aCGH) showed that all
mutation-negative cases had DNA copy number abnor-
malities (DCNAs), and the least aberrant, case 533, had
distinct loss of chromosome arm 1p (Figure 1A). No
samples showed evidence of homozygous deletion of
the TP53 locus (Figure 1B).
Pathology review of the mutation-negative cases
resulted in the re-classiﬁcation of case 60214 as
LGS carcinoma, case 23221 as high-grade carcinoma
of uncertain primary site, and case 533 as mixed
LGS/HGS type (Supporting information, Supplemen-
tary Table 2). Furthermore, aCGH analysis of cases
533 and 60214 did not show high-frequency DCNAs
that are typical of HGPSC [11]. The original diagno-
sis of HGPSC was conﬁrmed in the remaining four
cases (22029, 41358, 60049, and 60258). To further
exclude the possibility of pathological misclassiﬁca-
tion of endometrioid, clear cell or LGS tumours in the
mutation-negative cases, we also tested for mutations
commonly associated with these subtypes in KRAS
(exon 2), BRAF (exon 15), CTNNB1 (exon 3), and
PIK3CA (exons 10 and 21). Case 60214 had a mis-
sense mutation (G12C) in exon 2 of KRAS, consistent
with LGS origin. No other mutations were detected
(data not shown).
Other mutation-independent mechanisms of inacti-
vation of the p53 pathway were investigated. p53 is
targeted for degradation through the activity of MDM2
protein and is also regulated by the related MDM4
protein [13,14]. Ampliﬁcation of MDM2 is associated
with loss of p53 activity in some solid tumours [15,16].
aCGH analysis of the remaining four cases showed
copy number gain of MDM4 in cases 22029 and 60049,
and of MDM2 in case 60258 (Figure 1B). These obser-
vations were conﬁrmed by qPCR (Figure 1C). Inter-
estingly, both cases with MDM4 gain showed het-
erogeneous p53 immunostaining, including cytoplas-
mic staining (Figure 1D). Case 60258 with MDM2
gain showed strong nuclear staining for p53 protein
(Figure 1D). Interestingly, the remaining case with no
MDM2 or MDM4 gain (41358) showed strong nuclear
p53 immunostaining (Figure 1D).
In summary, the overall TP53 mutation rate for
selected HGPSC cases in the pilot and validation
cohorts was 94.4% (n = 119/126). After removing the
three mutation-negative cases with atypical or LGS
histology, the adjusted overall rate was 96.7% (n =
119/123). In the remaining four mutation-negative
HGPSC cases, three showed evidence of p53 dysfunc-
tion with increased p53 nuclear staining or cytoplasmic
mislocalization that was correlated with gains at the
MDM2/4 loci.
TP53 mutation type is not prognostic in HGPSC
It has been previously reported that the type of TP53
mutation may predict outcome in ovarian cancer [17].
Although our study was not adequately powered to
detect small effects, we tested for trends in the data.
For this analysis, we used all presumed HGPSC cases
from the pilot study and the validation cohort (n = 127,
n = 120 had TP53 mutation; Tables 3 and 4). There
was no indication of signiﬁcant association between
the frequency of TP53 mutation or the type of mutation
(missense versus not) and progression-free survival or
overall survival. Similarly, whether or not the missense
mutation affected the DNA binding motifs formed by
the L2 and L3 loops (codons 164–194 and 237–250,
respectively) or the LSH motifs (codons 119–135 and
272–287) [18] had no signiﬁcant effect on progression-
free survival or overall survival (Tables 3 and 4).
There was also no effect of codon 72 polymorphism
(Arg, Pro or heterozygous) on prognosis in any of
the HGPSCs with mutations (data not shown) or in
tumours with missense mutations (Tables 3 and 4).
There was no signiﬁcant interaction between the type
Table 3. The type of TP53 mutation does not inﬂuence progression-free survival
Index category (n) Comparison (n) Hazard ratio CI Log-rank p value
Mutant (120) Wild type (7) 1.4 0.6–3.1 0.5
Not missense (52) Missense (68) 0.9 0.6–1.4 0.8
DBM (44) NDBM (24) 1 0.6–1.7 1
DBM = DNA binding mutations; NDBM = non-DNA binding mutations.
Table 4. The type of TP53 mutation does not inﬂuence overall survival
Index category (n) Comparison (n) Hazard ratio CI Log-rank p value
Mutant (120) Wild type (7) 1.7 0.6–4.6 0.3
Not missense (52) Missense (68) 1 0.7–1.6 1
DBM (44) NDBM (24) 1.3 0.7–2.4 0.4
DBM = DNA binding mutations; NDBM = non-DNA binding mutations.
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of missense mutation (DNA binding or not) and codon
72 polymorphism (data not shown).
Discussion
By addressing the limitations of numerous other stud-
ies of TP53 mutation in ovarian cancer, we have
demonstrated for the ﬁrst time that HGPSCs have the
highest frequency of p53 mutation of any solid can-
cer. Approximately two-thirds of mutations occurred in
exons 5–8, known to be mutation hotspots for TP53.
By sequencing exons 2–4 and 9–11, we identiﬁed 22
mutations (n = 22/126, 17.5%) that would not have
otherwise been identiﬁed in our series and are poorly
represented in previous reports. The previously unre-
ported mutations that we have discovered are mostly
insertions/deletions predicted to result in truncated pro-
teins, but it is notable that HGPSC cases have frequent
involvement of exon 10 and speciﬁcally involvement
of position g.16915 (codon 342) in the oligomerization
domain of p53. This region also contains a putative
nuclear export signal for p53 and a recent study of
a novel missense mutation at codon 351 has shown
that K351N results in signiﬁcant loss of p53 tetramer-
ization, reduced BAX activation, and reduced nuclear
export of p53 [19]. Cytosolic export of p53 is required
for cisplatin-induced apoptosis in A2780 cells, suggest-
ing that combined loss of tetramerization and nuclear
export is critical for platinum resistance.
Of the mutation-negative cases, approximately half
were reclassiﬁed on pathological review as unrepresen-
tative of HGPSC, including two tumours that were LGS
and associated with borderline tumour. Serous cancers
may follow two distinct routes to malignancy [20]. A
minority of so-called type I tumours progress from bor-
derline tumours, whereas the majority of HGS (type
II) tumours arise with no evidence of LGS or border-
line tumours. Borderline serous tumours and their type
I invasive counterparts are generally low grade, have
relatively limited genomic DNA copy number change,
have frequent activating RAS pathway mutations, and
have substantially lower rates of TP53 mutation com-
pared with type II tumours [20–23]. Detailed analysis
of six cases of HGPSC arising from LGS and border-
line tumours showed no TP53 mutation [24]. Consis-
tent with this model, mutation-negative case 533 had
both LGS and HGS components and a bland aCGH
proﬁle.
Exclusion of LGS cases and mixed high-grade
serous cases increased the TP53 mutation frequency
to approximately 97% of HGPSCs. Of the remaining
mutation-negative cases, three may have had inactiva-
tion of the p53 pathway through chromosomal gain at
the MDM2 or MDM4 loci or potentially other genes
that alter p53 function in trans such as RFWD2 and
RCHY1 [25,26].
We are aware of over 70 publications that have
sought to relate TP53 mutation with clinical outcome
in ovarian cancer, with conﬂicting conclusions about
the importance of TP53 mutations for tumour aggres-
siveness, response to treatment, and survival. There is
no sign that a conclusion is at hand: since 2008, there
have been a number of papers relating TP53 mutation
and clinical outcome [27–30], with evidence presented
for [29] and against [28] mutation being a signiﬁ-
cant prognostic factor. A recent meta-analysis of 62
studies concluded that TP53 mutation had a modest
impact on survival in ovarian cancer but the effect was
insufﬁcient to support clinical application [4]. Whilst
meta-analyses such as that of de Graeff et al [4] have
the potential to detect subtle trends that may be missed
in all but the largest individual studies, they are con-
founded if there is a substantial false-negative rate, as
our ﬁndings indicate. Given the near ubiquitous occur-
rence of TP53 mutation, it difﬁcult to conclude that
it can be of signiﬁcant prognostic or predictive signif-
icance in HGPSC. We have not, however, excluded
the possibility that speciﬁc mutations can inﬂuence
prognosis or response to therapy, an important consid-
eration given the mounting evidence that some TP53
mutations have speciﬁc neomorphic functions [1]. It
is thought that inactivation of the p53 pathway is a
common, perhaps mandatory, event in all solid cancers
[31]. What is particularly unusual about HGPSC is an
almost total reliance on mutation TP53 itself for path-
way inactivation, perhaps reﬂecting the requirement
of certain tissues for neomorphic mutations for their
transformation [1]. Future work will need to address
interactions between speciﬁc mutations and other loci
such as PTEN and CDKN2A [32,33].
Our ﬁndings have important implications for the
new understanding of the pathogenesis of HGPSC.
p53 immunostaining and mutation appear to be a
feature of early-stage Fallopian tube lesions from
BRCA1/2 mutation carriers [7], suggesting that p53
dysfunction is essential for early tumourigenesis of
HGPSC. The notion that TP53 mutation is required
to allow survival of BRCA-deﬁcient ovarian precursor
lesions is consistent with the extremely high rates of
TP53 mutation in breast cancers arising in BRCA1
mutant women [34,35]. BRCA dysfunction may also
occur in sporadic HGPSC via a variety of inactivating
mechanisms but the very high rate of TP53 mutation
in our series of sporadic HGPSC cases suggests that
most are ‘BRCA-like’ with deﬁciencies for BRCA or
closely related DNA repair pathways [36].
It has become increasingly clear that ovarian cancer
is a series of distinctly different diseases with different
aetiologies [23,37] and that the development of reliable
biomarkers must be subtype-speciﬁc [38]. For example,
several biomarkers that appeared to be prognostic in a
cohort of all major subtypes of ovarian cancer were
not informative within homogeneous subtypes. Our
ﬁndings provide another example of the importance of
reﬁning the analysis of ovarian biomarkers by focusing
on the most clinically signiﬁcant group, HGPSC.
The key oncogenic and tumour suppressor genes for
HGPSC have not been identiﬁed and as it has high
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rates of genomic instability, many of the alterations
described may be passenger mutations. Our results for
the prevalence of TP53 mutation may be conserva-
tive as our prospectively determined selection criteria
excluded low-stage HGPSC cases (n = 15). This was
because true low-stage HGPSC is a rare entity and
often suggests misdiagnosis of LGS histiotype. How-
ever, 13/15 of these cases had TP53 mutation. Our
data are therefore consistent with mutant TP53 being
an essential driver mutation early in the pathogene-
sis of HGPSC. Future studies will need to focus on
studying the biological signiﬁcance of the different
types of TP53 mutation in HGPSC and developing p53
synthetic-lethal therapies for patients with this disease.
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